Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CEP-11981 (kinase inhibitor)
CEP-11981 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days. |
| Name | Type | Description |
|---|---|---|
| CEP-11981 (kinase inhibitor) | DRUG | Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence. |
Key Inclusion Criteria: The patient: * has a histologically or cytologically confirmed solid tumor that has relapsed or is refractory. Additionally, the tumor must be considered unresponsive or poorly responsive to accepted treatment modalities. * has a life expectancy of at least 12 weeks. * has ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CEP-11981 is an investigational small molecule kinase inhibitor being developed by Teva Pharmaceutical Industries Limited for the treatment of advanced cancer. It is a Phase 1 oncology candidate and has not been approved for any indication. CEP-11981 is also known as CEP-11981 (kinase inhibitor).
CEP-11981 targets the kinases FLT1, FLT4, KDR, and TEK. As an inhibitor, it acts on these targets, which are receptor tyrosine kinases involved in angiogenesis and vascular signaling. Targeting these kinases is the basis for its investigation in advanced cancer.
CEP-11981 is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program evaluating this kinase inhibitor in oncology.
CEP-11981 is in Phase 1 clinical development. It is an investigational agent and is not FDA approved. The Phase 1 program has been completed, with one completed trial and no active trials at this time.
CEP-11981 has been studied in one completed Phase 1 trial, NCT00875264. That open-label study was designed to determine the maximum tolerated oral dose of the kinase inhibitor CEP-11981 in patients with advanced cancer, and it enrolled 43 participants.
Yes, CEP-11981 (kinase inhibitor) is an alternative name for CEP-11981. Both names refer to the same investigational small molecule developed by Teva Pharmaceutical Industries Limited for advanced cancer.